An injectable drug used to reduce stubbornly high cholesterol levels appears in animal studies to also enhance the immune response of anti-cancer therapies known as immune checkpoint inhibitors, a study led by Duke Health ...
Nov 12, 2020
0
143
Cancer immunotherapies, which empower patients' immune systems to eliminate tumors, are revolutionizing cancer treatment. Many patients respond well to these treatments, sometimes experiencing long-lasting remissions. But ...
Oct 30, 2020
0
277
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset ...
Sep 10, 2020
0
62
For many individuals with different types of cancer, immune checkpoint inhibitors can effectively boost their immune system to fight their disease, but not all patients benefit from these medications. Now a team led by investigators ...
Sep 7, 2020
0
96
Cancer immunotherapy—empowering a patient's own immune system to clear away tumors on its own—holds great promise for some patients. But for other patients, immunotherapy just doesn't work.
Aug 17, 2020
0
121
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently ...
Jul 8, 2020
0
113
A drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be beneficial in a small study involving ten patients. The results, which appeared July 1, 2020, in Science ...
Jul 2, 2020
0
365
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, ...
Jun 17, 2020
0
99
One promising strategy to treat cancer is stimulating the body's own immune system to attack tumors. However, tumors are very good at suppressing the immune system, so these types of treatments don't work for all patients.
Jun 1, 2020
0
280
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged ...
Apr 1, 2020
0
144
